Article
作者: Chen, Xueqin ; Jin, Bo ; Li, Qingshan ; Lv, Dongqing ; Cheng, Ying ; Zhang, Jian ; Gu, Yanhong ; Hu, Weiguo ; Hu, Yanping ; Liu, Zhe ; An, Guangyu ; Zhao, Enfeng ; Ding, Yuli ; Yang, Runxiang ; Wang, Yongsheng ; Wang-Gillam, Andrea ; Yu, Yan ; Zhou, Jin ; Wang, Mengzhao ; Xiong, Jianping ; Zhao, Jun ; Hu, Changlu ; Shang, Yanhong ; Liu, Zhihua ; Zhuang, Wu ; Xing, Ligang ; Song, Zhengbo ; Li, Yongsheng ; Shi, Yuankai ; Ma, Rui ; Tang, Kejing ; Fang, Jian ; Zhao, Yanqiu ; Liu, Lian ; Rao, Zhiyue ; Li, Xingya ; Xia, Guohao ; Yu, Qitao ; Zhao, Hui ; Ba, Yi ; Li, Qiao ; Wang, Yinxiang ; Li, Zhihua ; Yao, Yu ; Wang, Zhen ; Wu, Lin ; Dai, Zhaoxia ; Bai, Chunmei ; Xing, Puyuan
Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRASG12C-mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC). Between 15 September 2022 and 28 September 2023, 119 patients with a median age of 62 years were enrolled. As of the data cut-off date on 28 March 2024, the ORR assessed by IRC was 47.9% (56/117; 95% confidence interval: 38.5-57.3%). The incidence of treatment-related adverse events (TRAEs) of any grade was 97.5% (116/119). The incidence of grades 3 and 4 TRAEs was 38.7% (46/119). A total of 5.0% (6/119) of patients discontinued the treatment due to TRAEs. No treatment-related deaths occurred. Glecirasib exhibited promising clinical efficacy and manageable safety profiles in these patient populations. ClinicalTrials.gov identifier: NCT05009329 .